Nephros (NASDAQ:NEPH) Shares Down 0.5%

Shares of Nephros, Inc. (NASDAQ:NEPH) traded down 0.5% during trading on Monday . The company traded as low as $1.97 and last traded at $1.99. 7,676 shares traded hands during trading, a decline of 62% from the average session volume of 20,068 shares. The stock had previously closed at $2.00.

Nephros Stock Down 0.5 %

The stock has a 50 day moving average price of $2.75 and a 200 day moving average price of $2.61. The stock has a market capitalization of $20.97 million, a price-to-earnings ratio of -13.27 and a beta of 1.31.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) EPS for the quarter. The company had revenue of $3.25 million during the quarter. Nephros had a negative return on equity of 18.25% and a negative net margin of 11.06%.

Hedge Funds Weigh In On Nephros

A number of hedge funds and other institutional investors have recently made changes to their positions in NEPH. Renaissance Technologies LLC lifted its stake in Nephros by 43.8% in the fourth quarter. Renaissance Technologies LLC now owns 32,064 shares of the company’s stock valued at $37,000 after buying an additional 9,764 shares during the period. Advisor Group Holdings Inc. lifted its stake in Nephros by 89.6% in the first quarter. Advisor Group Holdings Inc. now owns 8,674 shares of the company’s stock valued at $38,000 after buying an additional 4,100 shares during the period. Susquehanna International Group LLP acquired a new position in Nephros in the first quarter valued at approximately $39,000. Geode Capital Management LLC lifted its stake in Nephros by 595.0% in the second quarter. Geode Capital Management LLC now owns 77,344 shares of the company’s stock valued at $120,000 after buying an additional 66,216 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Nephros by 20.5% in the third quarter. Vanguard Group Inc. now owns 147,783 shares of the company’s stock valued at $134,000 after buying an additional 25,105 shares during the period. 41.10% of the stock is owned by institutional investors and hedge funds.

Nephros Company Profile

Nephros, Inc engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.